Diffuse Large B-cell lymphoma: Prognostic markers and their impact on therapy

Jamil, Muhammad Omer; Mehta, Amitkumar

doi:10.1586/17474086.2016.1146584

Cited by 24 publications

(19 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among 13 elder (≥70 years) patients with partial or complete response to MTX/rituximab-based induction, the median PFS has not been reached after 31.6 months of follow-up and no treatment-related death has been reported. [ 54 ] A similar result was found in relapsed patients administered maintenance lenalidomide. [ 55 ] Finally, a case report reported that nivolumab maintenance resulted in long-term remission of 18 months in a patient with multiple PCNSL relapses.…”

Section: Consolidation Treatmentsupporting

confidence: 64%

Primary central nervous system lymphoma: status and advances in diagnosis, molecular pathogenesis, and treatment

Zhang

Zhou²

2020

Chinese Medical Journal

View full text Add to dashboard Cite

Primary central nervous system lymphoma (PCNSL) is a rare group of extra-nodal non-Hodgkin lymphoma which is confined to the central nervous system or eyes. This article aims to present a brief profile of PCNSL diagnosis and treatment in immunocompetent patients. The authors retrieved information from the PubMed database up to September 2019. The annual incidence of PCNSL increased over the last four decades. The prognosis of PCNSL has improved mainly due to the introduction and wide-spread use of high-dose methotrexate, which is now the backbone of all first-line treatment polychemotherapy regimens. Gene expression profiling and next-generation sequencing analyses have revealed mutations that induce activation of nuclear factor-κB, B cell antigen receptor, and Janus kinases/signal transducer and activator of transcription proteins signal pathways. Some novel agents are investigated in the treatment of relapsed PCNSL including immunotherapy and targeted therapy. In particular, lenalidomide and ibrutinib have demonstrated durable efficiency. Treatment of PCNSL has evolved in the last 40 years and survival outcomes have improved in most patient groups, but there is still room to improve outcome by optimizing current chemotherapy and novel agents.

show abstract

Section: Consolidation Treatmentsupporting

confidence: 64%

Primary central nervous system lymphoma: status and advances in diagnosis, molecular pathogenesis, and treatment

Zhang

Zhou²

2020

Chinese Medical Journal

View full text Add to dashboard Cite

show abstract

“…These efforts have resulted in only slight improvements in characterization of low‐risk and high‐risk patients. In addition, various biomarkers, gene signatures, and molecular techniques could not replace the prognostic value of the clinically based IPI …”

Section: Introductionmentioning

confidence: 99%

Impact of comorbidities on outcomes of elderly patients with diffuse large B‐cell lymphoma

et al. 2017

View full text Add to dashboard Cite

International prognostic index (IPI) has remained the primary prognostic tool in diffuse large B cell lymphoma (DLBCL) for more than 20 years. Even though the disease is more common in older population, the impact of comorbidities, dose reductions, and treatment-related adverse events (TAEs) on the outcome in elderly DLBCL patients has not been well established. We studied 413 consecutive patients aged ≥ 60 years who were treated at the Cleveland Clinic. The median age at diagnosis was 69 years, 58% of patients had high IPI score, and 85% had low Charlson comorbidity index (CCI). Forty percent of patients required dose reductions during treatment, 78% achieved CR, and 70% experienced at least one grade II-IV TAE. High IPI score, high CCI, reduced dose chemotherapy, TAE, and hospitalization were significant predictors of death and relapse. In multivariable analysis, high IPI and CCI were independent predictors of overall and progression free survival. A simple model combining IPI and CCI could reliably distinguish three prognostically separate risk groups. Our results suggest that incorporation of CCI in current prognostic models can improve prognostication of older DLBCL patients and CCI might be a valuable tool in evaluating the eligibility of older patients for clinical trial enrollment.

show abstract

“…Non-Hodgkin's lymphoma (NHL) is a clonal proliferative disease of Β, T or natural killer cells which originate from lymph nodes or extranodal lymphatic tissue [1]. NHL comprises 4% of newly diagnosed cancer, and 90 % of lymphomas.…”

Section: Introductionmentioning

confidence: 99%

Clinical and pathological evaluation of histopathological subtypes in patients with non-Hodgkin’s lymphoma

2016

View full text Add to dashboard Cite

Objectives. Non-Hodgkin Lymphomas (NHLs) are tumours of the lymphoid system which originate from lymph nodes or extranodal lymphatic tissue. Since they represent a heterogeneous group of diseases, it is very important to determine prognostic factors apart from staging and identification of the patients with poor prognosis. The objective of our study is to investigate clinical characteristics, treatments applied, and their outcomes, survival rates, and prognostic factors which may be effective on survival. Methods. Clinical characteristics, treatments applied, and their outcomes, survivals, and prognostic factors which may be effective on the survival in 230 patients who were diagnosed as NHL, and consulted to our center between the years 2002, and 2015 were retrospectively evaluated. Results. Median age of our patients (male, 54.8 %, and female, 45.2 %) was 57 years. The most frequently seen histopathological subtype was diffuse large β cell lymphoma. We have seen that IPI score, β symptom, levels of LDH, albumin, β2 microglobulin, and lymphocyte counts are significant prognostic factors. Stomach was the most frequently involved extranodal organ. Advanced stage, higher IPI score, extranodal organ involvement were found to be correlated with shorter survival times. Conclusion. Everyday developments occur in the diagnosis, classification, and treatment of NHL. Therefore, it is important for medical centres to evaluate their treatment outcomes, and prognostic factors affecting their survival rates.Eur Res J 2016;2(1):52-61

show abstract

Diffuse Large B-cell lymphoma: Prognostic markers and their impact on therapy

Cited by 24 publications

References 75 publications

Primary central nervous system lymphoma: status and advances in diagnosis, molecular pathogenesis, and treatment

Primary central nervous system lymphoma: status and advances in diagnosis, molecular pathogenesis, and treatment

Impact of comorbidities on outcomes of elderly patients with diffuse large B‐cell lymphoma

Clinical and pathological evaluation of histopathological subtypes in patients with non-Hodgkin’s lymphoma

Contact Info

Product

Resources

About